Fungal echinocandin resistance
- PMID: 19770064
- PMCID: PMC2812698
- DOI: 10.1016/j.fgb.2009.09.003
Fungal echinocandin resistance
Abstract
The echinocandins are the newest class of antifungal agents in the clinical armory. These secondary metabolites are non-competitive inhibitors of the synthesis of beta-(1,3)-glucan, a major structural component of the fungal cell wall. Recent work has shown that spontaneous mutations can arise in two hot spot regions of Fks1 the target protein of echinocandins that reduce the enzyme's sensitivity to the drug. However, other strains have been isolated in which the sequence of FKS1 is unaltered yet the fungus has decreased sensitivity to echinocandins. In addition it has been shown that echinocandin-treatment can induce cell wall salvage mechanisms that result in the compensatory upregulation of chitin synthesis in the cell wall. This salvage mechanism strengthens cell walls damaged by exposure to echinocandins. Therefore, fungal resistance to echinocandins can arise due to the selection of either stable mutational or reversible physiological alterations that decrease susceptibility to these antifungal agents.
Copyright 2009 Elsevier Inc. All rights reserved.
Figures



Similar articles
-
Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus.mBio. 2019 Jun 4;10(3):e00779-19. doi: 10.1128/mBio.00779-19. mBio. 2019. PMID: 31164462 Free PMC article.
-
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.J Infect Dis. 2011 Aug 15;204(4):626-35. doi: 10.1093/infdis/jir351. J Infect Dis. 2011. PMID: 21791665 Free PMC article.
-
The Paradoxical Effect of Echinocandins in Aspergillus fumigatus Relies on Recovery of the β-1,3-Glucan Synthase Fks1.Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01690-16. doi: 10.1128/AAC.01690-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27872079 Free PMC article.
-
Resistance to echinocandin-class antifungal drugs.Drug Resist Updat. 2007 Jun;10(3):121-30. doi: 10.1016/j.drup.2007.04.002. Epub 2007 Jun 13. Drug Resist Updat. 2007. PMID: 17569573 Free PMC article. Review.
-
Echinocandin antifungal drugs in fungal infections: a comparison.Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000. Drugs. 2011. PMID: 21175238 Review.
Cited by
-
Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis.J Clin Microbiol. 2013 Sep;51(9):2964-9. doi: 10.1128/JCM.00903-13. Epub 2013 Jul 3. J Clin Microbiol. 2013. PMID: 23824764 Free PMC article.
-
The Cryptococcus wall: A different wall for a unique lifestyle.PLoS Pathog. 2023 Feb 23;19(2):e1011141. doi: 10.1371/journal.ppat.1011141. eCollection 2023 Feb. PLoS Pathog. 2023. PMID: 36821541 Free PMC article. No abstract available.
-
(1-aryloxy-2-hydroxypropyl)-phenylpiperazine derivatives suppress Candida albicans virulence by interfering with morphological transition.Microb Biotechnol. 2018 Nov;11(6):1080-1089. doi: 10.1111/1751-7915.13307. Epub 2018 Sep 17. Microb Biotechnol. 2018. PMID: 30221456 Free PMC article.
-
Fitness trade-offs restrict the evolution of resistance to amphotericin B.PLoS Biol. 2013 Oct;11(10):e1001692. doi: 10.1371/journal.pbio.1001692. Epub 2013 Oct 29. PLoS Biol. 2013. PMID: 24204207 Free PMC article.
-
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?Intensive Care Med. 2014 Sep;40(9):1241-55. doi: 10.1007/s00134-014-3404-7. Epub 2014 Aug 5. Intensive Care Med. 2014. PMID: 25091787 Review.
References
-
- Agarwal A.K., Rogers P.D., Baerson S.R., Jacob M.R., Barker K.S., Cleary J.D., Walker L.A., Nagle D.G., Clark A.M. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J. Biol. Chem. 2003;278:34998–35015. - PubMed
-
- Al Fattani M.A., Douglas L.J. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 2006;55:999–1008. - PubMed
-
- Arendrup M.C., Garcia-Effron G., Buzina W., Mortensen K.L., Reiter N., Lundin C., Jensen H.E., Lass-Florl C., Perlin D.S., Bruun B. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 2009;53:1185–1193. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases